TY - JOUR A1 - Schroeder, Katharina A1 - Meyer-ter-Vehn, Tobias A1 - Fassnacht-Riederle, Heidi A1 - Guthoff, Rainer T1 - Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report JF - Journal of Medical Case Reports N2 - Background: Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures. Case presentation: We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance. Conclusions: The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment. KW - multifocal choroiditis KW - chorioretinal lesions KW - secondary CNV KW - bevacizumab KW - systemic immunosuppression KW - case report Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-171317 VL - 10 IS - 298 ER - TY - JOUR A1 - Mansour, Ahmad M. A1 - Arevalo, J. Fernando A1 - Al Kahtani, Eman A1 - Zegarra, Hernando A1 - Abboud, Emad A1 - Anand, Rajiv A1 - Ahmadieh, Hamid A1 - Sisk, Robert A. A1 - Mirza, Salman A1 - Tuncer, Samuray A1 - Navea Tejerina, Amparo A1 - Mataix, Jorge A1 - Ascaso, Francisco J. A1 - Pulido, Jose S. A1 - Guthoff, Rainer A1 - Goebel, Winfried A1 - Roh, Young Jung A1 - Banker, Alay S. A1 - Gentile, Ronald C. A1 - Alonso Martinez, Isabel A1 - Morris, Rodney A1 - Panday, Neeraj A1 - Min, Park Jung A1 - Merce, Emilie A1 - Lai, Timothy Y. Y. A1 - Massoud, Vicky A1 - Ghazi, Nicola G. T1 - Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma JF - Journal of Ophtamology N2 - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma. KW - membrane KW - photodynamic therapy KW - secondary KW - bevacizumab KW - ranibizumab KW - patient Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117923 IS - 210458 ER - TY - JOUR A1 - Freiberg, Florentina Joyce A1 - Matlach, Juliane A1 - Grehn, Franz A1 - Karl, Sabine A1 - Klink, Thomas T1 - Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy JF - Clinical Ophthalmology N2 - Purpose: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated. Methods: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab. Results: Group 1 had 6.4 ± 3.3 (0–15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0–12) (mean ± standard deviation and range, respectively) 5-FU injections. The added injection of bevacizumab significantly reduced the mean number of 5-FU injections by 2.4 ± 3.08 (P ≤ 0.005). There was no significantly lower IOP in group 2 when compared to group 1. A significant reduction in vascularization and in cork screw vessels could be found in both groups (P < 0.0001, 7 days to last 5-FU), yet there was no difference between the two groups at the last follow-up. Postoperative complications were significantly higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between preoperative to last follow-up could be found between the two groups. Conclusion: The postoperative injection of bevacizumab reduced the number of subconjunctival 5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP reduction, bleb morphology, and postoperative medication was not detected. KW - bevacizumab KW - 5-fluorouracil KW - glaucoma KW - trabeculectomy KW - bleb failure KW - bleb scarring Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96546 ER -